Lund (Sweden), September 12, 2013. Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that a biomarker trend analysis of overall survival (OS) and Progression Free Survival (PFS) from the ANYARA Phase II/III study in renal cell cancer will be presented at the scientific conference "European Cancer Congress 2013" (ECCO-ESMO-ESTRO) held in Amsterdam, the Netherlands, September 27 - October 1.
Help employers find you! Check out all the jobs and post your resume.
